Induction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative breast carcinomas.

<h4>Background</h4>Tamoxifen is still the most widely used drug in hormone therapy for the treatment of breast cancer. Its benefits in adjuvant treatment are well documented in controlled and randomized clinical studies, which have demonstrated an increase in disease-free intervals of pa...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Valentina Folgiero, Paolo Avetrani, Giulia Bon, Selene E Di Carlo, Alessandra Fabi, Cecilia Nisticò, Patrizia Vici, Elisa Melucci, Simonetta Buglioni, Letizia Perracchio, Isabella Sperduti, Laura Rosanò, Ada Sacchi, Marcella Mottolese, Rita Falcioni
Format: article
Langue:EN
Publié: Public Library of Science (PLoS) 2008
Sujets:
R
Q
Accès en ligne:https://doaj.org/article/66d59f94593e4c78821476da0f2174ef
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!